vs

Side-by-side financial comparison of Guidewire Software, Inc. (GWRE) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Guidewire Software, Inc. is the larger business by last-quarter revenue ($332.6M vs $207.3M, roughly 1.6× Ultragenyx Pharmaceutical Inc.). Guidewire Software, Inc. runs the higher net margin — 9.4% vs -62.0%, a 71.4% gap on every dollar of revenue. On growth, Guidewire Software, Inc. posted the faster year-over-year revenue change (26.5% vs 25.9%). Guidewire Software, Inc. produced more free cash flow last quarter ($-72.3M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 17.5%).

Guidewire Software, Inc., commonly Guidewire, is an American software company based in San Mateo, California. It offers an industry platform for property and casualty (P&C) insurance carriers in the U.S. and worldwide.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

GWRE vs RARE — Head-to-Head

Bigger by revenue
GWRE
GWRE
1.6× larger
GWRE
$332.6M
$207.3M
RARE
Growing faster (revenue YoY)
GWRE
GWRE
+0.6% gap
GWRE
26.5%
25.9%
RARE
Higher net margin
GWRE
GWRE
71.4% more per $
GWRE
9.4%
-62.0%
RARE
More free cash flow
GWRE
GWRE
$28.5M more FCF
GWRE
$-72.3M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
17.5%
GWRE

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
GWRE
GWRE
RARE
RARE
Revenue
$332.6M
$207.3M
Net Profit
$31.3M
$-128.6M
Gross Margin
63.0%
Operating Margin
5.6%
-54.7%
Net Margin
9.4%
-62.0%
Revenue YoY
26.5%
25.9%
Net Profit YoY
242.6%
3.5%
EPS (diluted)
$0.36
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GWRE
GWRE
RARE
RARE
Q4 25
$332.6M
$207.3M
Q3 25
$356.6M
$159.9M
Q2 25
$293.5M
$166.5M
Q1 25
$289.5M
$139.3M
Q4 24
$262.9M
$164.6M
Q3 24
$291.5M
$139.5M
Q2 24
$240.7M
$147.0M
Q1 24
$240.9M
$108.8M
Net Profit
GWRE
GWRE
RARE
RARE
Q4 25
$31.3M
$-128.6M
Q3 25
$52.0M
$-180.4M
Q2 25
$46.0M
$-115.0M
Q1 25
$-37.3M
$-151.1M
Q4 24
$9.1M
$-133.2M
Q3 24
$16.8M
$-133.5M
Q2 24
$-5.5M
$-131.6M
Q1 24
$9.7M
$-170.7M
Gross Margin
GWRE
GWRE
RARE
RARE
Q4 25
63.0%
Q3 25
65.0%
Q2 25
62.2%
Q1 25
61.9%
Q4 24
60.2%
Q3 24
64.0%
Q2 24
59.1%
Q1 24
59.1%
Operating Margin
GWRE
GWRE
RARE
RARE
Q4 25
5.6%
-54.7%
Q3 25
8.3%
-106.9%
Q2 25
1.5%
-64.8%
Q1 25
4.0%
-102.6%
Q4 24
-1.8%
-74.3%
Q3 24
3.5%
-94.6%
Q2 24
-6.9%
-79.1%
Q1 24
-5.2%
-151.9%
Net Margin
GWRE
GWRE
RARE
RARE
Q4 25
9.4%
-62.0%
Q3 25
14.6%
-112.8%
Q2 25
15.7%
-69.0%
Q1 25
-12.9%
-108.5%
Q4 24
3.5%
-80.9%
Q3 24
5.7%
-95.7%
Q2 24
-2.3%
-89.5%
Q1 24
4.0%
-156.8%
EPS (diluted)
GWRE
GWRE
RARE
RARE
Q4 25
$0.36
$-1.28
Q3 25
$0.61
$-1.81
Q2 25
$0.54
$-1.17
Q1 25
$-0.45
$-1.57
Q4 24
$0.11
$-1.34
Q3 24
$0.21
$-1.40
Q2 24
$-0.07
$-1.52
Q1 24
$0.12
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GWRE
GWRE
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$1.0B
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.5B
$-80.0M
Total Assets
$2.6B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GWRE
GWRE
RARE
RARE
Q4 25
$1.0B
$421.0M
Q3 25
$1.1B
$202.5M
Q2 25
$920.4M
$176.3M
Q1 25
$1.2B
$127.1M
Q4 24
$1.3B
$174.0M
Q3 24
$1.0B
$150.6M
Q2 24
$782.3M
$480.7M
Q1 24
$777.6M
$112.3M
Total Debt
GWRE
GWRE
RARE
RARE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$398.9M
Q2 24
Q1 24
Stockholders' Equity
GWRE
GWRE
RARE
RARE
Q4 25
$1.5B
$-80.0M
Q3 25
$1.5B
$9.2M
Q2 25
$1.4B
$151.3M
Q1 25
$1.3B
$144.2M
Q4 24
$1.3B
$255.0M
Q3 24
$1.3B
$346.8M
Q2 24
$1.3B
$432.4M
Q1 24
$1.3B
$140.3M
Total Assets
GWRE
GWRE
RARE
RARE
Q4 25
$2.6B
$1.5B
Q3 25
$2.7B
$1.2B
Q2 25
$2.5B
$1.3B
Q1 25
$2.5B
$1.3B
Q4 24
$2.6B
$1.5B
Q3 24
$2.2B
$1.5B
Q2 24
$2.0B
$1.6B
Q1 24
$2.0B
$1.3B
Debt / Equity
GWRE
GWRE
RARE
RARE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.30×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GWRE
GWRE
RARE
RARE
Operating Cash FlowLast quarter
$-67.4M
$-99.8M
Free Cash FlowOCF − Capex
$-72.3M
$-100.8M
FCF MarginFCF / Revenue
-21.7%
-48.6%
Capex IntensityCapex / Revenue
1.5%
0.5%
Cash ConversionOCF / Net Profit
-2.15×
TTM Free Cash FlowTrailing 4 quarters
$286.0M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GWRE
GWRE
RARE
RARE
Q4 25
$-67.4M
$-99.8M
Q3 25
$244.8M
$-91.4M
Q2 25
$32.4M
$-108.3M
Q1 25
$86.0M
$-166.5M
Q4 24
$-62.3M
$-79.3M
Q3 24
$193.8M
$-67.0M
Q2 24
$4.8M
$-77.0M
Q1 24
$69.3M
$-190.7M
Free Cash Flow
GWRE
GWRE
RARE
RARE
Q4 25
$-72.3M
$-100.8M
Q3 25
$241.4M
$-92.7M
Q2 25
$31.6M
$-110.7M
Q1 25
$85.2M
$-167.8M
Q4 24
$-63.1M
$-79.5M
Q3 24
$192.1M
$-68.6M
Q2 24
$4.1M
$-79.0M
Q1 24
$66.3M
$-193.9M
FCF Margin
GWRE
GWRE
RARE
RARE
Q4 25
-21.7%
-48.6%
Q3 25
67.7%
-58.0%
Q2 25
10.8%
-66.5%
Q1 25
29.4%
-120.5%
Q4 24
-24.0%
-48.3%
Q3 24
65.9%
-49.2%
Q2 24
1.7%
-53.7%
Q1 24
27.5%
-178.2%
Capex Intensity
GWRE
GWRE
RARE
RARE
Q4 25
1.5%
0.5%
Q3 25
1.0%
0.8%
Q2 25
0.2%
1.5%
Q1 25
0.3%
1.0%
Q4 24
0.3%
0.1%
Q3 24
0.6%
1.2%
Q2 24
0.3%
1.4%
Q1 24
1.2%
3.0%
Cash Conversion
GWRE
GWRE
RARE
RARE
Q4 25
-2.15×
Q3 25
4.71×
Q2 25
0.70×
Q1 25
Q4 24
-6.82×
Q3 24
11.56×
Q2 24
Q1 24
7.15×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GWRE
GWRE

Subscription$222.7M67%
Services$62.4M19%
Other$33.1M10%
Support$14.5M4%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons